Skip to main content
Contact Us
Subscribe
E-Edition
65°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Argenx Se ADR
(NQ:
ARGX
)
529.95
-13.04 (-2.40%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Argenx Se ADR
< Previous
1
2
3
4
5
6
7
8
9
Next >
Biotech Stocks : Are You A Trader Or A Longer Term Investor?
October 01, 2024
Biotech bull market is intact as indicated by large cap biopharma and the best performing funds.
Via
Talk Markets
Peeling Back The Layers: Exploring argenx Through Analyst Insights
September 26, 2024
Via
Benzinga
Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases
September 25, 2024
Amgen tested its drug, Uplizna, in generalized myasthenia gravis, a market where Argenx's Vyvgart leads.
Via
Investor's Business Daily
Snowflake, Hawaiian Electric Industries And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
September 24, 2024
Via
Benzinga
Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB
August 29, 2024
Johnson & Johnson has submitted a Biologics License Application (BLA) to the FDA for nipocalimab, seeking its first global approval for generalized myasthenia gravis (gMG). This submission follows...
Via
Benzinga
Exposures
Product Safety
What 25 Analyst Ratings Have To Say About argenx
August 23, 2024
Via
Benzinga
The Analyst Verdict: argenx In The Eyes Of 27 Experts
July 29, 2024
Via
Benzinga
Breaking Down argenx: 12 Analysts Share Their Views
May 10, 2024
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
August 12, 2024
Via
Benzinga
This CrowdStrike Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
August 06, 2024
Via
Benzinga
Northrop Grumman To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday
July 29, 2024
Via
Benzinga
Why Is European Drugmaker Argenx Stock Trading Higher On Monday?
June 24, 2024
The FDA has approved Argenx's Vyvgart Hytrulo for chronic inflammatory demyelinating polyneuropathy, with projections of $1.2 billion in U.S. revenues by 2030.
Via
Benzinga
Exposures
Product Safety
Argenx Surges After Its Bread-And-Butter Drug Wins Another FDA Approval
June 24, 2024
This is the second approval for the biotech company's drug, Vyvgart Hytrulo.
Via
Investor's Business Daily
Exposures
Product Safety
The Analyst Verdict: argenx In The Eyes Of 12 Experts
April 18, 2024
Via
Benzinga
Key Takeaways From argenx Analyst Ratings
March 26, 2024
Via
Benzinga
Micron To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Monday
June 24, 2024
Via
Benzinga
RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
June 24, 2024
Via
Benzinga
After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay
May 30, 2024
Immunovant, which jumped Wednesday on news from rival Biohaven, reversed course Thursday.
Via
Investor's Business Daily
Biohaven Stock Stumbles As Protein-Degrading Drug Falls Short Of Expectations In Early-Stage Study
May 29, 2024
Biohaven shares drop as interim data from the Phase 1 study of BHV-1300 fell short of investor expectations.
Via
Benzinga
Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump
May 29, 2024
The company says it's still running additional testing of the drug, calling the results "positive."
Via
Investor's Business Daily
Why Duolingo Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
May 09, 2024
Via
Benzinga
Why AppLovin Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
May 09, 2024
Via
Benzinga
ARGX Stock Earnings: argenx Misses EPS, Misses Revenue for Q1 2024
May 09, 2024
ARGX stock results show that argenx missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Exact Sciences Reports Q1 Loss, Joins Beyond Meat, Duolingo And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
May 09, 2024
Via
Benzinga
Cartesian Therapeutics' Rare Disease Candidate Shows Long Lasting Benefit Over Argenx's Vyvgart, Analyst Initiates With Buy
April 10, 2024
Cartesian Therapeutics' autoimmune disease treatment with re-dosable mRNA CAR-Ts. Learn about Descartes-08, a promising anti-BCMA CAR-T therapy offering deeper, longer-lasting efficacy than current...
Via
Benzinga
Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday
March 26, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Why FactSet Research Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
March 21, 2024
Shares of FactSet Research Systems Inc. (NYSE: FDS) fell sharply during Thursday’s session after the company reported worse-than-expected second-quarter revenue and issued FY24 guidance.
Via
Benzinga
Guess? Posts Upbeat Earnings, Joins Lufax, Nortech Systems And Other Big Stocks Moving Higher On Thursday
March 21, 2024
U.S. stocks were higher, with the Dow Jones index gaining around 250 points on Thursday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Is European Pharma Giant Argenx Valued At Over $20B Trading Higher On Thursday?
March 21, 2024
Argenx shares rise on Chugai's gMG trial disappointment. FDA-approved Vyvgart for anti-acetylcholine receptor antibody-positive adult patients. Enspryng's Phase 3 study results disappoint. Vyvgart...
Via
Benzinga
Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results
March 21, 2024
Investors saw Chugai's experimental drug as a potential rival to Argenx's approved medicine, Vyvgart.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.